Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$684 Mln
P/E Ratio
--
P/B Ratio
0.98
Industry P/E
--
Debt to Equity
--
ROE
-0.17 %
ROCE
-15.56 %
Div. Yield
0 %
Book Value
7.68
EPS
-1.39
CFO
$771.51 Mln
EBITDA
$845.76 Mln
Net Profit
$180.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
| -47.48 | -18.92 | -42.40 | -60.40 | -30.39 | -13.43 | -14.27 |
|
BSE Sensex*
| 2.73 | 3.83 | 4.72 | 7.65 | 12.10 | 19.69 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
| -28.17 | 31.91 | -47.43 | 39.57 | -27.38 | -6.33 | -15.28 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.69 | 10,202.62 | 12.01 | 12.69 | |
| 72.33 | 10,025.34 | 96.83 | 2.52 | |
| 163.14 | 8,863.93 | -- | -25.23 | |
| 296.91 | 11,513.99 | 277.87 | 3.65 |
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and... pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116 Read more
CEO, President & Director
Mr. Paul J. Diaz
CEO, President & Director
Mr. Paul J. Diaz J.D.
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Myriad Genetics Inc (MYGN) stood at -- as on 31-Dec-24
The share price of Myriad Genetics Inc (MYGN) is $7.20 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Myriad Genetics Inc (MYGN) has given a return of -30.39% in the last 3 years.
Myriad Genetics Inc (MYGN) has a market capitalisation of $ 684 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Myriad Genetics Inc (MYGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Myriad Genetics Inc (MYGN) and enter the required number of quantities and click on buy to purchase the shares of Myriad Genetics Inc (MYGN).
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116
The CEO & director of Mr. Paul J. Diaz. is Myriad Genetics Inc (MYGN), and CFO & Sr. VP is Mr. Paul J. Diaz J.D..
There is no promoter pledging in Myriad Genetics Inc (MYGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Myriad Genetics Inc. (MYGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.15
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-15.2
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Myriad Genetics Inc (MYGN) was $0 Mln.
$-0.30
(
